Premium
IC‐P‐088: FUNCTIONAL AND STRUCTURAL DEGENERATIONS OF THE CENTRAL OLFACTORY SYSTEM IN AD AND MCI: AN EARLY MARKER
Author(s) -
Yang Qing X.
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.093
Subject(s) - hippocampus , atrophy , neurocognitive , olfactory system , neuroscience , olfaction , pathological , psychology , dementia , olfactory memory , audiology , medicine , cognition , central nervous system , pathology , olfactory bulb , disease
significantly worse than Stage 0 on challenging tests of memory for names (FNAME p1⁄40.042) and occupations (FNAME p1⁄40.033), 2 nd list learning on the Memory Capacity Test (MCT DR, p1⁄40.017), executive function (working memory WM, p1⁄40.016; Letter Number Sequencing LNSq , p1⁄40.027) and naming (BNT p1⁄40.026). Stage 2 performed significantly worse than Stage 0 on more standard memory tests such as the Free and Cued Selective Reminding Test (FRsrt p1⁄40.015; FCsrt p1⁄40.010) and worse than Stage 1 on challenging memory (MCT IR p1⁄40.029, MCT DR p1⁄40.009 andMCT CR p1⁄40.002) and executive function tests (LNSq p1⁄40.001, Trails A p1⁄40.034 andWM p1⁄40.042). SNAP performed similar to Stage 0 on standard and challenging memory tests but worse on executive tests (fluency, p1⁄40.031,WM p1⁄40.012, and LNSq p1⁄40.030).Conclusions: These findings suggest that subtle cognitive changes are associated with different biomarker stages in CN older adults.Amyloidosis is associated with impairment on both challengingmemory and executive tests. Neurodegeneration is associated with more executive dysfunction than memory. The combination of amyloidosis and neurodegeneration results in more significant decline in memory and executive performance.